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The awake-asleep-awake (AAA) technique for awake cranio-
tomy is still a mainstream technique using total intravenous 
anesthesia (TIVA) [1]. Unlike conventional GABA-mimetic 
sedatives, some of the key features of dexmedetomidine, an α2- 
receptor agonist that acts upon the pontine locus coeruleus, are 
attractive for the AAA technique. Allowing the patient to wake-
up easily and perform tasks when aroused and then go back 
to sleep when not stimulated, providing sedative, anxiolytic, 
and analgesic effects, and most importantly not depressing 
the respiratory system and interfering electrophysiologically 
at an optimal clinical dose are some of the key features of 
dexmedetomidine [2]. Unfortunately, there are few randomized 
clinical trials on dexmedetomidine and the regimen for 
dexmedetomidine combined with other anesthetics does not 
seem to have a clear consensus yet. Since dexmedetomidine 
has only recently been introduced to Korea, dexmedetomidine 
was cautiously administered using four different regimens 
with or without other intravenous anesthetics according to the 
procedural requirements (Table 1) for the AAA technique. All 
patients tolerated the entire procedure for awake craniotomy, 
and cortical speech mapping and neurocognitive testing were 
immediately possible after stopping dexmedetomidine and 
propofol infusion (patient 1), were possible twenty minutes 
after discontinuing remifentanil and propofol (patient 2), 
and were possible twenty-one minutes after propofol and 
dexmedetomidine infusion (patient 3 and 4). Interestingly, 
episodes of respiratory holding occurred in one patient and 
there were discordances between the OAA/S score and BIS in 
all patients, perhaps due to lower values of BIS than expected 
(Table 1). Of note, apnea and severe respiratory depression 
were reported previously for dexmedetomidine after general 
anesthesia [3,4]. The underlying causes of res  piratory depression 
by dexmedetomidine are unclear. Given the fact that respiratory 
depression occurred while the residual effects of the general 
anesthetics probably remained, dexmedetomidine might 
enhance the respiratory depression of the GABA-mimetic 
sedatives due to a decreased volume of the distribution of the 
anesthetics. Anyway, dexmedetomidine seems not to be free 
from respiratory depression and requires a critically examination 
of whether dexmedetomidine depresses the respiratory 
system, especially in combination with other anesthetics. 
Additionally, regarding the subjective and objective measuring 
tools for degrees of sedation such as BIS or OAA/S and their 
correlation, a sedation level below an OAA/S of 3 could not be 
achieved with dexmedetomidine alone and administration 
of other anesthetics such as propofol was needed during the 
asleep period. Meanwhile, the BIS values swiftly ranged in the 
90s and below 50 in three patients during the asleep period 
when the OAA/S score was 2-3 with dexmedetomidine 
combined with propofol. Interestingly, the BIS value decreased 
to 10 with an OAA/S of 4-5 in patient 2 during the awake 
period with dexmedetomidine infusion alone. Therefore, the 
validity of BIS for measuring the level of sedation when using 
dexmedetomidine needs to be reconsidered. 
 In conclusion, we describe four regimens using the AAA 
technique with dexmedetomidine for awake craniotomy, 
which allowed for the successful cooperation of the patients 
and cortical mapping during the awake period; however, 
dexmedetomidine was not free from respiratory depression and 
its clinical features are not consistent with those of traditional 
GABA-mimetic sedatives. 
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Table 1. Summary of the Anesthetic Regimens Used and Clinical Features 
Asleep period Awake period Asleep period
Patient 1
Patient 2
Patient 3
Patient 4
D: 0.5-1.0 μg/kg/hr without loading dose
P: bolus + TCI, Ce 0.5 μg/ml 
R: 0.03-0.10 μg/kg/hr
BIS (70-95)
OAA/S (2-5)
Episode of respiratory holding
D: loading 0.35 μg/kg over 10 minutes + 
  0.25-0.5 μg/kg/hr
P: Ce, 0.3 μg/ml, TCI
R: Ce, 0.3 ng/ml, TCI
BIS (30-75)
OAA/S (2-3)
D: loading 1 μg/kg over 20 minutes + 
  0.5-0.7 μg/kg/hr
P: 2 μg/kg/hr + bolus
R: 0.04-0.07 μg/kg/hr
BIS (50-75)
OAA/S (2-3)
D: loading 1 μg/kg over 10 minutes + 
  0.25-1 μg/kg/hr
P: 2 μg/kg/hr
R: not used
BIS (34-70)
OAA/S (2)
D: 0.1 μg/kg/hr 
P: not used
R: not used
Osnervan 4 mg
BIS  (80-99)
OAA/S (4)
D: 0.1-2.0 μg/kg/hr
P: not used
R: not used
BIS (10-99)
OAA/S (4)
D: not used
P: not used
R: 0.04-0.07 μg/kg/hr
BIS (75-85)
OAA/S (4)
D: not used
P: not used
R: not used
BIS (95-100)
OAA/S (4-5)
D: 0.1-1.0 μg/kg/hr
P: TCI, Ce 0.1-1.3 μg/ml
R: 0.03-0.10  μg/kg/hr
BIS (58-98)
OAA/S (2-3)
D: 0.5-2.0 μg/kg/hr
P: Ce 0.3-0.5 μg/ml, TCI
R: Ce, 0.3-0.5 ng/ml, TCI
BIS (65-95)
OAA/S (2)
D: 0.4 μg/kg/hr
P: 2 mg/kg/hr
R: 0.02-0.07 μg/kg/hr
BIS (60-90)
OAA/S (2-4)
D: 0.5 μg/kg loading over 5 min + 
  0.15-0.25 μg/kg/hr
P: 0.8-2 mg/kg/hr
BIS (50-80)
OAA/S (3)
OAA/S: observed assessment of alertness scale; 0: no response to pain, 1: no response to mild prodding or shaking, 2: responds to mild 
prodding or shaking, 3: responds to loud or repeated voicing of instructions, 4: respondsslowly to a voice with a normal tone, 5: readily responds 
to a voice with a normal tone.